Literature DB >> 15711776

Osteoporosis case finding in the general practice: phalangeal radiographic absorptiometry with and without risk factors for osteoporosis to select postmenopausal women eligible for lumbar spine and hip densitometry.

Katharina M Gasser1, Christian Mueller, Marcel Zwahlen, Manfred Kaufmann, Gaby Fuchs, Romain Perrelet, Gilbert Abetel, Ulrich Bürgi, Kurt Lippuner.   

Abstract

Mass screening for osteoporosis using DXA measurements at the spine and hip is presently not recommended by health authorities. Instead, risk factor questionnaires and peripheral bone measurements may facilitate the selection of women eligible for axial bone densitometry. The aim of this study was to validate a case finding strategy for postmenopausal women who would benefit most from subsequent DXA measurement by using phalangeal radiographic absorptiometry (RA) alone or in combination with risk factors in a general practice setting. The sensitivity and specificity of this strategy in detecting osteoporosis (T-score < or =2.5 SD at the spine and/or the hip) were compared with those of the current reimbursement criteria for DXA measurements in Switzerland. Four hundred and twenty-three postmenopausal women with one or more risk factors for osteoporosis were recruited by 90 primary care physicians who also performed the phalangeal RA measurements. All women underwent subsequent DXA measurement of the spine and the hip at the Osteoporosis Policlinic of the University Hospital of Berne. They were allocated to one of two groups depending on whether they matched with the Swiss reimbursement conditions for DXA measurement or not. Logistic regression models were used to predict the likelihood of osteoporosis versus "no osteoporosis" and to derive ROC curves for the various strategies. Differences in the areas under the ROC curves (AUC) were tested for significance. In women lacking reimbursement criteria, RA achieved a significantly larger AUC (0.81; 95% CI 0.72-0.89) than the risk factors associated with patients' age, height and weight (0.71; 95% C.I. 0.62-0.80). Furthermore, in this study, RA provided a better sensitivity and specificity in identifying women with underlying osteoporosis than the currently accepted criteria for reimbursement of DXA measurement. In the Swiss environment, RA is a valid case finding tool for patients with risk factors for osteoporosis, especially for those who do not qualify for DXA reimbursement.

Entities:  

Mesh:

Year:  2005        PMID: 15711776     DOI: 10.1007/s00198-005-1846-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  46 in total

1.  Effective dose values in bone mineral measurements by photon absorptiometry and computed tomography.

Authors:  W A Kalender
Journal:  Osteoporos Int       Date:  1992-03       Impact factor: 4.507

2.  Radiographic absorptiometry: a simple method for determination of bone mass.

Authors:  F Cosman; B Herrington; S Himmelstein; R Lindsay
Journal:  Osteoporos Int       Date:  1991-10       Impact factor: 4.507

3.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

4.  Radiographic absorptiometry for bone mineral measurement of the phalanges: precision and accuracy study.

Authors:  S O Yang; S Hagiwara; K Engelke; M S Dhillon; G Guglielmi; E J Bendavid; O Soejima; D L Nelson; H K Genant
Journal:  Radiology       Date:  1994-09       Impact factor: 11.105

5.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

6.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

Review 7.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

8.  The Canadian SCORE questionnaire: optimizing the use of technology for low bone density assessment. Simple Calculated Osteoporosis Risk Estimate.

Authors:  W J Ungar; R Josse; S Lee; N Ryan; R Adachi; D Hanley; J Brown; M C Breton
Journal:  J Clin Densitom       Date:  2000       Impact factor: 2.963

9.  How well do radiographic absorptiometry and quantitative ultrasound predict osteoporosis at spine or hip? A cost-effectiveness analysis.

Authors:  K Lippuner; G Fuchs; A G Ruetsche; R Perrelet; J P Casez; I Neto
Journal:  J Clin Densitom       Date:  2000       Impact factor: 2.963

10.  Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women.

Authors:  Adolfo Díez-Pérez; Fernando Marín; Joan Vila; Mercedes Abizanda; Artur Cervera; Cristina Carbonell; Rosa Ma Alcolea; Adoración Cama; Teresa Rama; Elena Galindo; Carmen Olmos
Journal:  J Clin Densitom       Date:  2003       Impact factor: 2.963

View more
  3 in total

1.  Quantitative ultrasound and radiographic absorptiometry are associated with vertebral deformity in Japanese Women: the Hizen-Oshima study.

Authors:  Y Abe; N Takamura; Z Ye; M Tomita; M Osaki; Y Kusano; T Nakamura; K Aoyagi; S Honda
Journal:  Osteoporos Int       Date:  2010-06-29       Impact factor: 4.507

2.  Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.

Authors:  M Schwenkglenks; K Lippuner
Journal:  Osteoporos Int       Date:  2007-05-26       Impact factor: 4.507

3.  Screening and prevention in Swiss primary care: a systematic review.

Authors:  David Eisner; Marco Zoller; Thomas Rosemann; Carola A Huber; Nina Badertscher; Ryan Tandjung
Journal:  Int J Gen Med       Date:  2011-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.